Loading
Latest filing published 10 Feb 2026 for Zentalis Pharmaceuticals, Inc., €62k.
Vincent Vultaggio is a declared insider of Zentalis Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). Between 4 October 2024 and 10 February 2026, the trades on record add up to 8 filings.
On the market, this insider has only sold: 7 sales, €98k in total. The rest of the record consists of 1 share grant. Since January 2026: no purchases and 5 sales on the market.
On 10 February 2026 came the latest disclosure, an open-market sale for €6,829 in Zentalis Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations